加上我们最近宣布的与Regeneron和Genentech合作的免疫肿瘤学研究,2017年将是变革的一年,为重要疗效数据的多重机会奠定了基础。” 信源地址:http://ir.inovio.com/news/news-releases/news-releases-details/2017/Inovio-Begins-Phase-3-Clinical-Trial-of-VGX-3100-for-the-Treatment-of-HPV-Related-Cervical-Pre-...
时至今日,Adam对该药物的看法依旧是上述意见。Adam在24日发布Twitter上称:“Inovio再一次成为“伟大的”试验。我们想一下,2期3100人的试验延期完成,现在3期试验又被FDA叫停。” 参考REFERENCE [1] Inovio Announces FDA Request for Additional Information For P...
研究结果表明,VGX-3100能够有效治疗不同HPV引发的疾病。INOVIO公司将在美国阴道镜及宫颈病理学会(ASCCP)年会的网络会议环节发表此项研究结果,名为VGX-3100治疗HPV16/18导致的肛门HSIL的非盲、二期研究的初步结果(Preliminary Results of an Open-label Phase 2 Study of VGX-3100 for the Treatment of HPV16 and/...
(HPV-301) Phase 3 clinical trial of VGX-3100 were not statistically significant, the REVEAL 1 and REVEAL 2 studies alone would unlikely be supportive of a marketing authorization for VGX-3100. The FDA indicated that the subsequent conduct of one or two adequate and well-controlled trials in ...
VGX-3100, now in a Phase 3 trial, is an HPV-specific immunotherapy that is being developed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV infection. VGX-3100 is designed to ...
Immunotherapy that significantly impacts the clinical status of advanced cervical intraepithelial neoplasia (CIN) has the potential to provide physicians an important alternative to surgery to treat CIN 2/3 disease. Our previous two Phase I studies of VGX3100, a highly optimised DNA immunotherapy for ...
Here we report the results of a Phase II study assessing the safety and efficacy of VGX-3100 in 167 women with biopsy-proven CIN 2/3 with concurrent HPV16/18 infection. The randomized, placebo-controlled, double-blind study evaluated cervical tissue changes after three 6 mg intramuscular doses...
We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. ...
Phase 2b results of HPV immunotherapy VGX-3100 announced
VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo controlled phase 2b studyObjectives: Assessment of the safety, efficacy and immunogenicity of VGX-3100 in women with biopsy-proven CIN2/3 withHPV16 ...